SynCardia Total Artificial Heart Sustains Patient 1,636 Days Before Transplant
A 29-year-old patient endured 1,636 days of continuous support from the SynCardia Total Artificial Heart before undergoing donor heart transplant on February 24, 2026. Picard Medical’s device replaced both ventricles and maintained circulation, highlighting its ability to sustain critically ill biventricular heart failure patients over four years.
1. Patient Achieves Record 1,636-Day Support
A 29-year-old was implanted with the SynCardia Total Artificial Heart on September 2, 2021 to treat severe biventricular heart failure and remained on device support for 1,636 days before receiving a donor heart transplant on February 24, 2026.
2. Device Function and Therapy Role
The SynCardia Total Artificial Heart replaces both ventricles and all four native heart valves, maintaining systemic circulation and hemodynamic stability as a bridge to transplant for patients ineligible for left ventricular assist devices.
3. Regulatory and Clinical Milestones
Picard Medical develops and commercializes the world’s first total artificial heart approved by both FDA and Health Canada, underscoring its clinical safety profile and long-term mechanical circulatory support capabilities.
4. Global Implant Footprint
More than 2,100 SynCardia Total Artificial Heart implants have been performed across 27 countries, with individual support durations exceeding eight years in selected patients.